News
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 trial titled Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback